Matthew P Fraser

US Patent:

7115606, Oct 3, 2006

Filed:

Jun 7, 2004

Appl. No.:

10/863770

Inventors:

Steven B. Landau - Wellesley MA, US
Cheryl L. Miller - Natick MA, US
Matthew O. Fraser - Apex NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Waltham MA

International Classification:

A61K 31/496

US Classification:

514249

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

US Patent:

20050020577, Jan 27, 2005

Filed:

Jun 7, 2004

Appl. No.:

10/863771

Inventors:

Steven Landau - Wellesley MA, US
Cheryl Miller - Natick MA, US
Matthew Fraser - Apex NC, US

International Classification:

A61K031/551
A61K031/519

US Classification:

514218000, 514252160, 514260100

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

US Patent:

20050272719, Dec 8, 2005

Filed:

May 4, 2005

Appl. No.:

11/122940

Inventors:

Steven Landau - Wellesley MA, US
Cheryl Miller - Natick MA, US
Matthew Fraser - Apex NC, US

International Classification:

A61K031/519
A61K031/551

US Classification:

514218000, 514252160, 514260100

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

US Patent:

20050282799, Dec 22, 2005

Filed:

May 6, 2005

Appl. No.:

11/124580

Inventors:

Steven Landau - Wellesley MA, US
Cheryl Miller - Natick MA, US
Matthew Fraser - Apex NC, US

International Classification:

A61K031/551
A61K031/519

US Classification:

514218000, 514260100, 514252160

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

US Patent:

6846823, Jan 25, 2005

Filed:

Apr 2, 2004

Appl. No.:

10/817332

Inventors:

Steven B. Landau - Wellesley MA, US
Cheryl L. Miller - Natick MA, US
Matthew O. Fraser - Apex NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Waltham MA

International Classification:

A01N 4354

US Classification:

514249

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.